Hypomagnesemia and the risk of new-onset diabetes after liver transplantation

Liver Transplantation

Volumn 16, Issue 11, 2010, Pages 1278-1287

  Van Laecke, Steven ^a   Desideri, Federico ^a,b   Geerts, Anja ^a   Van Vlierberghe, Hans ^a   Berrevoet, Frederik ^a   Rogiers, Xavier ^a   Troisi, Roberto ^a   De Hemptinne, Bernard ^a   Vanholder, Raymond ^a   Colle, Isabelle ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CORTICOSTEROID; CYCLOSPORIN; GLUCOSE; INSULIN; MAGNESIUM; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; BODY WEIGHT; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; DRUG BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HYPERGLYCEMIA; HYPOMAGNESEMIA; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEW ONSET DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYTOMEGALOVIRUS INFECTIONS; DIABETES MELLITUS; FEMALE; GRAFT SURVIVAL; HUMANS; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; MAGNESIUM; MALE; METABOLIC DISEASES; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RISK; RISK FACTORS; TACROLIMUS; YOUNG ADULT;

EID: 78349289295     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22146     Document Type: Article

References (30)

1. Marchetti P., New-onset diabetes after liver transplantation: from pathogenesis to management. Liver Transpl 2005; 11: 612 - 620.
2. Saliba F, Lakehal M, Pageaux GP, Roche B, Vanlemmens C, Duvoux C, et al. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. Liver Transpl 2007; 13: 136 - 144.
3. Pagadala M, Dasarathy S, Eghtesad B, McCullough AJ., Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl 2009; 15: 1662 - 1670.
4. Zein NN, Abdulkarim AS, Wiesner RH, Egan KS, Persing DH., Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol 2000; 32: 209 - 217.
5. Moon JI, Barbeito R, Faradji RN, Gaynor JJ, Tzakis AG., Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: long-term follow up. Transplantation 2006; 82: 1625 - 1628.
6. Van, Laecke S, Van, Biesen W, Verbeke F, De, Bacquer D, Peeters P, Vanholder R., Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant 2009; 9: 2140 - 2149.
7. Margreiter R., Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741 - 746.
8. Vannini SD, Mazzola BL, Rodoni L, Truttmann AC, Wermuth B, Bianchetti MG, et al. Permanently reduced plasma ionized magnesium among renal transplant recipients on cyclosporine. Transpl Int 1999; 12: 244 - 249.
9. Nijenhuis T, Hoenderop JG, Bindels RJ., Downregulation of Ca(2+) and Mg(2+) transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia. J Am Soc Nephrol 2004; 15: 549 - 557.
10. Koivisto M, Valta P, Hockerstedt K, Lindgren L., Magnesium depletion in chronic terminal liver cirrhosis. Clin Transplant 2002; 16: 325 - 328.
11. Mather HM, Nisbet JA, Burton GH, Poston GJ, Bland JM, Bailey PA, Pilkington TR., Hypomagnesaemia in diabetes. Clin Chim Acta 1979; 95: 235 - 242.
12. Pham PC, Pham PM, Pham SV, Miller JM, Pham PT., Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007; 2: 366 - 373.
13. Nadler JL, Buchanan T, Natarajan R, Antonipillai I, Bergman R, Rude R., Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 1993; 21: 1024 - 1029.
14. Barbagallo M, Dominguez LJ., Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. Arch Biochem Biophys 2007; 458: 40 - 47.
15. Kramer JH, Spurney C, Iantorno M, Tziros C, Mak IT, Tejero-Taldo MI, et al. Neurogenic inflammation and cardiac dysfunction due to hypomagnesemia. Am J Med Sci 2009; 338: 22 - 27.
16. Kao WH, Folsom AR, Nieto FJ, Mo JP, Watson RL, Brancati FL., Serum and dietary magnesium and the risk for type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Arch Intern Med 1999; 159: 2151 - 2159.
17. Guerrero-Romero F, Rascon, -Pacheco RA, Rodriguez-Moran M, de la Pena JE, Wacher N., Hypomagnesaemia and risk for metabolic glucose disorders: a 10-year follow-up study. Eur J Clin Invest 2008; 38: 389 - 396.
18. Song Y, Manson JE, Buring JE, Liu S., Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. Diabetes Care 2004; 27: 59 - 65.
19. He K, Liu K, Daviglus ML, Morris SJ, Loria CM, Van Horn L, et al. Magnesium intake and incidence of metabolic syndrome among young adults. Circulation 2006; 113: 1675 - 1682.
20. Chacko SA, Song Y, Nathan L, Tinker L, de Boer IH, Tylavsky F, et al. Relations of dietary magnesium intake to biomarkers of inflammation and endothelial dysfunction in an ethnically diverse cohort of postmenopausal women. Diabetes Care 2010; 33: 304 - 310.
21. Stegall MD, Everson G, Schroter G, Bilir B, Karrer F, Kam I., Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation 1995; 60: 1057 - 1060.
22. Driscoll CJ, Cashion AK, Hathaway DK, Thompson C, Conley Y, Gaber O, et al. Posttransplant diabetes mellitus in liver transplant recipients. Prog Transplant 2006; 16: 110 - 116.
23. Hjelmesaeth J, Sagedal S, Hartmann A, Rollag H, Egeland T, Hagen M, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004; 47: 1550 - 1556.
24. Hjelmesaeth J, Muller F, Jenssen T, Rollag H, Sagedal S, Hartmann A., Is there a link between cytomegalovirus infection and new-onset posttransplantation diabetes mellitus? Potential mechanisms of virus induced beta-cell damage. Nephrol Dial Transplant 2005; 20: 2311 - 2315.
25. Nordøy I, Müller F, Nordal KP, Rollag H, Lien E, Aukrust P, Froland SS., The role of the tumor necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients. J Infect Dis 2000; 181: 51 - 57.
26. Jaeckel E, Manns M, Von HM., Viruses and diabetes. Ann N Y Acad Sci 2002; 958: 7 - 25.
27. Saab S, Shpaner A, Zhao Y, Brito I, Durazo F, Han S, et al. Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation. Am J Transplant 2006; 6: 1890 - 1895.
28. Kishi Y, Sugawara Y, Tamura S, Kaneko J, Matsui Y, Makuuchi M., New-onset diabetes mellitus after living donor liver transplantation: possible association with hepatitis C. Transplant Proc 2006; 38: 2989 - 2992.
29. Tueche SG., Diabetes mellitus after liver transplant new etiologic clues and cornerstones for understanding. Transplant Proc 2003; 35: 1466 - 1468.
30. Ryzen E, Servis KL, DeRusso P, Kershaw A, Stephen T, Rude RK., Determination of intracellular free magnesium by nuclear magnetic resonance in human magnesium deficiency. J Am Coll Nutr 1989; 8: 580 - 587.